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DOI 10.1016/j.ccr.2011.06.001SUMMARYSomatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant
proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating
TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development
have not been delineated. We report here an animal model of conditional Tet2 loss in the hematopoietic
compartment that leads to increased stem cell self-renewal in vivo as assessed by competitive transplant
assays. Tet2 loss leads to a progressive enlargement of the hematopoietic stem cell compartment and even-
tual myeloproliferation in vivo, including splenomegaly, monocytosis, and extramedullary hematopoiesis. In
addition, Tet2+/ mice also displayed increased stem cell self-renewal and extramedullary hematopoiesis,
suggesting that Tet2 haploinsufficiency contributes to hematopoietic transformation in vivo.INTRODUCTION
Genetic studies of patients withmyeloidmalignancies have iden-
tified recurrent somatic alterations in themajority of patients with
myeloproliferative neoplasms (MPNs), myelodysplastic syn-
dromes (MDSs), and acute myeloid leukemia (AML). A subset
of myeloid disease alleles can be classified into two distinctSignificance
Recurrent somatic mutations in TET2 and in other genes that r
with myeloid malignancies and in other cancers. However, the
model. We report here that Tet2 loss leads to increased stem
Consistent with human mutational data, Tet2 loss leads to mye
cytic proliferation. In addition, haploinsufficiency for Tet2 confe
that the monoallelic TET2 mutations found in most patients c
strates that reduction in TET2 expression or function lea
transformation.complementation groups: one class that includes mutations
that activate oncogenic signaling pathways, and a second class
of mutations that perturbs myeloid differentiation (Gilliland and
Griffin, 2002). However, recent studies have suggested that
this model of myeloid transformation does not accurately repre-
sent the biologic and clinical heterogeneity of MPN, MDS, and
AML, and that not all leukemogenic disease alleles can beegulate the epigenetic state have been identified in patients
effects of Tet2 loss have not yet been studied in an in vivo
cell self-renewal and to progressive stem cell expansion.
loproliferation in vivo, notable for splenomegaly and mono-
rs increased self-renewal andmyeloproliferation, suggesting
an contribute to myeloid transformation. This work demon-
ds to enhanced stem cell function in vivo and myeloid
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Tet2 Controls HSC Development and Transformationclassified by their ability to directly affect signaling and/or differ-
entiation. Consonant with this notion, recent studies have identi-
fied recurrent mutations of known and putative epigenetic
modifiers in patients with myeloid malignancies. These include
somatic mutations in chromatin-modifying enzymes (Ernst
et al., 2010; Nikoloski et al., 2010) and in DNAmethyltransferases
(Ley et al., 2010; Yamashita et al., 2010). In addition, biologic
studies of recurrent chromosomal translocations, including
MLL fusions, have shown that leukemogenic fusion proteins alter
epigenetic regulation in hematopoietic cells, resulting in changes
in chromatin state at specific loci (Dorrance et al., 2006; Krivtsov
et al., 2008). Taken together, these data suggest that somatic
alterations in genes that regulate the epigenetic state of hemato-
poietic cells are a common pathogenetic event in leukemogen-
esis (Abdel-Wahab and Levine, 2010). Importantly, recent
studies have identified recurrent mutations in epigenetic master
regulators in lymphoid malignancies (Morin et al., 2010) and in
solid tumors (van Haaften et al., 2009; Varela et al., 2011), sug-
gesting that mutational dysregulation of the epigenetic
machinery is a common theme in oncogenic transformation.
Recent studies have identified a novel class of somatic muta-
tions in myeloid malignancies. Specifically, somatic deletions
and loss-of-function mutations in the ten-eleven translocation
2 (TET2) gene were identified in 10%–20% of patients with
MDS and MPN (Delhommeau et al., 2009; Langemeijer et al.,
2009); subsequent studies identified recurrent TET2 mutations
in patients with chronic myelomonocytic leukemia (CMML) and
AML (Abdel-Wahab et al., 2009; Jankowska et al., 2009), and
demonstrated that TET2 mutations were associated with
adverse outcome in intermediate-risk AML (Metzeler et al.,
2011). Within the TET family of proteins, TET1, TET2, and TET3
have been shown to modify DNA by hydroxylating 5-methylcyto-
sine (5mC) (Ko et al., 2010; Tahiliani et al., 2009), and the TET2
mutant proteins observed in these patients with myeloid malig-
nancies have been shown to be deficient in this enzymatic func-
tion (Ko et al., 2010). In addition, recent work demonstrated that
mutations in the metabolic enzymes IDH1 and IDH2 (Mardis
et al., 2009; Parsons et al., 2008; Ward et al., 2010; Yan et al.,
2009) are mutually exclusive with TET2 mutations, and that
production of 2-hydroxyglutarate by neomorphic IDH1/2 mutant
proteins (Dang et al., 2009) inhibits TET2 catalytic activity (Fig-
ueroa et al., 2010; Xu et al., 2011). Taken together, these data
indicate that mutations that impair 5-hydroxymethylation repre-
sent a novel mechanism of transformation in myeloid
malignancies.
Although there are extensive genetic data implicating TET2
mutations in myeloid transformation, the consequences of Tet2
loss in hematopoietic development have not been delineated.
Recent in vitro studies using shRNA-based approaches have
suggested a role for TET2 in regulating myeloid differentiation
(Figueroa et al., 2010; Ko et al., 2010) and in regulating stem/
progenitor cell proliferation (Figueroa et al., 2010). In order to
elucidate the function of Tet2 in hematopoiesis in vivo, we
describe here the characterization of conditional deletion of
Tet2 in the hematopoietic compartment demonstrating a role
for Tet2 in regulating hematopoietic stem cell renewal and differ-
entiation. These findings provide a model for human disease in
which the loss of Tet2, often through the loss of a single allele,
leads to increased self-renewal and myeloid transformation,12 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.and provides insight into how mutations in epigenetic modifiers
contribute to malignant transformation.
RESULTS
Tet2-Expression Silencing Leads to Increased Replating
Capacity
We first investigated the effects of Tet2 silencing in hematopoi-
esis by transducing whole mouse bone marrow cells with retro-
viral vectors encoding validated Tet2 shRNA vectors (Figueroa
et al., 2010), and sorting for GFP-positive cells. Stable shRNA-
mediated knockdown led to stable reductions in TET2 expres-
sion by 50%–70% (Figure 1A). Because TET2 is an enzyme
that hydroxylates 5mC on DNA, its knockdown should lead to
loss of 5-hydroxylation of methylcytosine (5hmC). We used
a mass spectrometry-based approach (Shah et al., 2010) to
demonstrate that Tet2 silencing results in a significant reduction
in 5hmC in GFP+ hematopoietic cells stably expressing Tet2
shRNAs (Figure 1B). GFP+ cells were then plated in methylcellu-
lose for CFU in vitro assays. We observed no significant differ-
ences in the number or the lineage specificity of Tet2-expressing
and Tet2-silenced colonies after the first plating. However, at the
second plating there was a 2-fold increase in the number of colo-
nies expressing Tet2-specific shRNAs (Figure 1C). Strikingly,
Tet2-silenced cells retained the ability to serially replate and
generate colonies, although essentially no wild-type colonies
were detected after the second plating. In agreement with the
putative acquisition of a more immature phenotype, Tet2
shRNA-expressing colonies upregulated c-Kit, a hematopoietic
stem and progenitor cell marker (Figure 1D). These initial studies
demonstrated that Tet2 silencing reduces global 5hmC levels
and increases the replating capacity of hematopoietic stem
and progenitor cells.
Generation of a Conditional Tet2 Knockout Allele
Although these studies provide important information on TET2
function, hematopoiesis is a dynamic process that is most accu-
rately studied in vivo. Thus, we decided to conditionally inhibit
Tet2 gene expression in the hematopoietic compartment. We
first assessed Tet2 expression by performing qRT-PCR of sorted
hematopoietic stem/progenitor subsets (LSK: Lin Sca-1+
c-Kit+; common myeloid progenitor [CMP]: Lin Sca-1c-Kit+,
FcgRlo CD34+; GMP: Lin Sca1 c-Kit+ FcgR+CD34+, MEP:
Lin Sca-1 c-Kit+ FcgR-CD34) and in differentiated hemato-
poietic lineages. Expression studies revealed that Tet2 expres-
sion was ubiquitously expressed in the hematopoietic compart-
ment, including in stem and progenitor subsets and in mature
myeloid and lymphoid cells (Figure 2A). Purified human CD34+
peripheral blood-mobilized cells also demonstrated expression
of TET2 in human hematopoietic stem cells (see Figure S1A
available online). Two different TET2 isoforms are expressed,
including a shorter isoform b that lacks the C-terminal enzymatic
domain. To understand the nature and location of TET2 muta-
tions in human myeloid malignancies and how this would inform
our mouse model, we analyzed TET2 mutations from 991
patients with a variety of myeloid malignancies (MPN, CMML,
and AML). Exon 3 in the murine Tet2 locus encodes for approx-
imately half of the TET2 protein; analysis from the mutational
data identifies the corresponding exon 3 of human TET2 as the
Figure 1. In Vitro Tet2-Expression Silencing
Leads to Increased Serial Replating
(A) Quantification of the shRNA-mediated Tet2
knockdown efficiency using qRT-PCR.
(B) Quantification of 5hmC by LC/MS of control
(MSCV-IRES-GFP) versus Tet2 knockdown-
derived cells after retroviral transduction and GFP
sorting.
(C) CFU assay of bone marrow-derived cells in-
fected with control or Tet2 shRNA virus. Colony
counts were scored every 14 days.
(D) Upregulation of surface c-Kit expression in
progenitors expressing Tet2-specific shRNA. *p <
0.026. Error bars represent ± SD.
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Tet2 Controls HSC Development and Transformationmost frequently mutated exon in myeloid malignancies,
including a large number of nonsense mutations, insertions,
and deletion mutations that truncate the protein. Specifically,
we found that 41.5% (51 of 123) of TET2 mutations occurred in
the first coding exon of TET2 (exon 3), whereas 29.3% (36 of
123) of TET2 mutations occurred in the last coding exon (exon
11) (Abdel-Wahab et al., 2009; Figueroa et al., 2010) (Figure 2B;
Figure S1B). Moreover, the largest proportion of mutations that
results in a premature stop codon occurs in exon 3 (Figure 2B).
In addition, exon 3 of Tet2 is contained within the two described
Tet2 transcripts (Tet2a and Tet2b), which are both expressed in
the hematopoietic compartment (Figure S1A). Therefore, we
decided to target exon 3 using homologous recombination. We
utilized ES cell targeting to insert two LoxP sites flanking exon
3, as well as an Frt-flanked neomycin selection cassette in the
upstream intron (Figure 2C). The generated mice (Tet2f/f) were
initially crossed to a germline Flp-deleter murine line to eliminate
the neomycin cassette, and then subsequently crossed to IFNa-
inducible Mx1-cre, the hematopoietic-specific Vav-cre, and the
germline EIIa-cre mice (Ku¨hn et al., 1995; Lakso et al., 1996;
Stadtfeld and Graf, 2005). Figures 2D and 2E demonstrate the
efficient targeting of the locus and the generation of a recom-
bined (E) allele upon Cre recombinase expression in hematopoi-
etic cells. Although Tet2 was recently suggested to play an
important role in ES cell differentiation (Ito et al., 2010; Koh
et al., 2011), EIIa-cre+Tet2/ mice were born with the expected
Mendelian ratios with normal growth and organ development.
These data suggested that other members of the Tet family
may have redundant functions in embryonic development and
in homeostasis of different tissues. Vav-Cre-mediated deletion
led to a compete silencing of Tet2 expression in the bone
marrow, thymus, and spleen of Vav-cre+Tet2f/f animals. Interest-
ingly, Tet2-expression silencing was not accompanied by
changes in expression of either Tet1 or Tet3, whichwere both ex-
pressed in hematopoietic cells at similar levels before and after




Given that RNAi-mediated Tet2 silencing
led to increased replating potential, we
assessed whether deletion of TET2 in
different hematopoietic subsets led tosimilar effects. We performed methylcellulose CFU assays using
FACS-sorted Linc-Kit+ progenitors and LSK CD150+ HSC from
Vav-cre+Tet2/ and Vav-cre+Tet2+/+ mice. In both cases, Tet2-
deficient cells demonstrated serial replating capacity (for at least
ten replatings followed by continuous liquid culture for 4 addi-
tional months), whereas Tet2+/+ counterparts differentiated and
did not generate colonies after the second plating (Figure 3A).
Tet2/ colonies were more homogeneous and less differenti-
ated and contained cells with a promyeloblastic morphology
(Figure 3B). Indeed, expression of c-Kit, a classical marker of
hematopoietic progenitors and the receptor for stem cell factor,
was upregulated significantly in Tet2/ and was expressed in
nearly all Tet2/ cells in the third plating and beyond (Figure 3C).
Furthermore, the c-Kit-expressing cells also upregulated the
myeloid progenitor markers CD34 and FcgR (Figure 3C). Inter-
estingly, comparison of gene expression profiles of Tet2/ cells
at the fifth plating (CFU5) to different stem and progenitor popu-
lations showed that Tet2/ cells share a common gene expres-
sion programwith CMPs, suggesting that these are indeed c-Kit+
myeloid progenitors with the ability to replate indefinitely in
culture (Figure S2). Tet2/ myeloid progenitor cells were also
characterized by increased expression of the self-renewal regu-
lators Meis1 and Evi1, and by reduced expression of multiple
myeloid-specific factors (including Cebpa, Cebpd, Mpo, and
Csf1), more consistent with multipotent LSK cells than
committedCMPorGMP (Figure S2; data not shown). These find-
ings are consistent with the shRNA knockdown experiments
shown in Figure 1 and suggest that Tet2 loss leads to enhanced
serial replating ability in vitro.
Tet2 Deletion Leads to Progressive Defects
in Hematopoiesis
We next performed detailed analysis of in vivo hematopoiesis in
Tet2/ mice. Detailed phenotypic characterization of young
(4–6 weeks) Vav-Cre+Tet2/ mice failed to reveal gross
alterations in bone marrow stem/progenitor numbers or in the1–24, July 12, 2011 ª2011 Elsevier Inc. 13
Figure 2. Generation of a Conditional Tet2 allele
(A) qRT-PCR showing relative expression levels of Tet2 in purified progenitor and mature mouse hematopoietic stem and progenitor subsets.
(B) Exon distribution of TET2 mutations found in patients with AML and CMML.
(C) Schematic depiction of the targeted Tet2 allele. Exon 3 is targeted and flanked by LoxP sites upon Frt-mediated deletion of the NEO cassette.
(D) Verification of correct homologous recombination using Southern blots on targeted ES cells.
(E) Verification of VavCre-mediated excision using genomic PCR. Recombined (D), floxed, and wild-type Tet2 alleles are shown.
(F) Efficiency of Tet2 knockout using qRT-PCR in purified bone marrow c-Kit+ cells, total thymus, and spleen. Expression of Tet1 and Tet3 in wild-type and
Tet2-deficient bone marrow cells reveals no differences in Tet1 and Tet3 expression with Tet2 deletion. Error bars represent ± SD.
See also Figure S1.
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Tet2 Controls HSC Development and Transformationmyeloid compartment (Figure 4A, first panel). Likewise, there
were no effects on the differentiation of lymphocyte lineages in
the bone marrow (data not shown). However, detailed FACS
analysis of Tet2/ spleens from young mice identified signifi-14 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.cant extramedullary hematopoiesis, as defined by a significant
increase in the absolute numbers of c-Kit+ (data not shown),
LSK cells (including CD150+ HSC), and myeloid progenitors
(Figures 4B and 4C). Moreover, purification of Tet2+/+ and
Figure 3. Tet2 Deficiency Leads to
Increased Serial Replating Ability In Vitro
(A) Left panel shows a methylcellulose CFU assay
using LSK CD150+-purified cells. Absolute
number of colonies is shown at different platings.
A similar CFU assay using Lineagec-Kit+ cells is
shown in the right panel.
(B) Morphology of generated colonies either at the
2nd or 4th plating. Cytospins of the colonies are
shown.
(C) Left panels illustrate upregulation of surface c-
Kit expression at the 2nd and 4th plating. Right
panels show cell surface expression of CD34 and
FcgR on LincKit+ Tet2/ cells by the 4th plating.
A representative example of at least three inde-
pendent experiments is shown for each assay.
Error bars represent ± SD.
See also Figure S2.
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Tet2 Controls HSC Development and TransformationTet2/ bone marrow progenitor populations (LSK, CMP, GMP)
and subsequent transcriptome analysis revealed that Tet2/
LSK cells display a significant enrichment of a CMPgene expres-
sion signature (Figure S3; Experimental Procedures), suggesting
that Tet2 loss leads to aberrant hematopoiesis in vivo.
We next analyzed older (20 week) Tet2/ animals to deter-
mine the consequences of Tet2 loss on long-term hematopoi-
esis. At 20 weeks after Tet2 deletion, we noted an increase in
the size of the bone marrow LSK compartment (Figure 4A,
second panel). This phenotype was not accompanied by expan-
sion of a specific stem or multipotential progenitor compartment
as defined by the utilization of CD150/CD48 marker labeling.
Further analysis of the progenitor compartment showed
a marked increase in the GMP population, which includes
progenitors of monocytes and granulocytes (Figure 4A).
However, the most striking effects of Tet2 deletion were noted
in the spleen of these animals; Tet2/ but not Tet2+/+ mice dis-
played splenomegaly at 20 weeks of age, which was associatedCancer Cell 20, 1with an increase in the proportion of total
CD11b+ cells (see below). Notably, extra-
medullary hematopoiesis was prominent,
with a significant increase in the absolute
number of LSK (Figures 4B and 4C) as
well as CD150+ HSC (not shown) cells.
These combined studies suggested that
Tet2 deletion leads to progressive
defects in blood differentiation and to
a significant elevation of extramedullary
hematopoiesis.
Tet2-Deficient Hematopoietic Stem
Cells Show Increased Self-Renewal
Ability In Vivo
Because we have previously shown that
Tet2 deletion leads to increased replating
capacity in vitro, we tested the ability of
Tet2/ cells to compete directly against
wild-type counterparts in an in vivo
transplantation setting. We mixed iden-
tical numbers of either Mx1-cre+-
Tet2WT/WTCD45.2+ or Mx1-cre+Tet2f/fCD45.1+/CD45.2+ BM from littermate mice with wild-type
CD45.1+ bone marrow and transplanted them in lethally irradi-
ated CD45.1+ recipients (Figure 5A). Four weeks after transplan-
tation, equal engraftment (approximately 50:50) rates were de-
tected in peripheral blood, and subsequently, Tet2 deletion
was induced by polyI-polyC injections. The presence of the
Tet2-recombined allele was verified using genomic PCR of
peripheral blood mononuclear cells. Chimerism was followed
by FACS assessment of peripheral blood staining for CD45.1
versus CD45.2 (or CD45.1+45.2+). As evident from Figure 5B,
upon Tet2 deletion, Tet2/ chimerism increased rapidly
because these cells outcompeted their wild-type counterparts.
Indeed, at 23 weeks after polyI-polyC deletion, more than 95%
of the peripheral blood cells (both myeloid and lymphoid) were
Tet2/ (Figure 5C). To define in detail the developmental stage
in which Tet2/ cells outcompete Tet2-expressing cells, we
have analyzed transplanted recipients 23 weeks after polyI-
polyC injection. Analysis of the LT-HSC compartment indicated1–24, July 12, 2011 ª2011 Elsevier Inc. 15
Figure 4. Tet2 Deletion Leads to Progressive Defects in Bone Marrow and Extramedullary Hematopoiesis
(A) FACS analysis of bone marrow stem and progenitor populations of Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) at two different ages (4–6 and
20 weeks). Antibody stainings are as indicated.
(B) Identical antibody labeling as in (A) but using spleen cells from Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) mice.
(C) Absolute numbers of spleen LSK cells in Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) mice at two different ages. p values are shown for each
comparison. For all experiments shown in this figure, there are eight for each genotype. Error bars represent ± SD.
See also Figure S3.
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Tet2 Controls HSC Development and Transformationthat that the vast majority (>90%) of these cells were Tet2/,
suggesting that TET2-deficient HSC has the ability to outcom-
pete wild-type counterparts. Once established, this bias toward
the Tet2/ cells was also observed in downstream bone16 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.marrow multipotent progenitors (MPP1,2), myeloid progenitors
(CMP), bone marrow mature CD11b+ monocytes, and B220+
lymphocytes (Figures 5D and 5E). Competitive transplant studies
using VavCre+-Tet2/ HSC demonstrated that TET2-deficient
Cancer Cell
Tet2 Controls HSC Development and Transformationcells outcompeted wild-type cells to a similar extent, further sup-
porting our previous findings (Figure S4). These studies confirm
that Tet2 function regulates the self-renewal of adult HSC.
Tet2-Deficient Animals Develop CMML-like Disease
We next performed a detailed phenotypic analysis of
Tet2/VavCre+ mice 20 weeks after deletion. We found that
Tet2/ animals, but not Tet2+/+ littermates, were characterized
by progressive leukocytosis; this was associated with neutro-
philia and a marked increase in peripheral monocyte counts
(Figures 6A and 6B and Table 1; Table S1). Peripheral blood anal-
ysis revealed that by week 20, approximately 70%of the Tet2/
VavCre+mice developed significant peripheral blood monocyto-
sis (Figure S5). Myeloid dysplasia was apparent in both bone
marrow and peripheral lymphoid tissue, as defined by myeloid
left shift (presence of blasts, promyelocytes, myelocytes, or
metamyelocytes). In addition, presence of hypogranular cyto-
plasm or abnormal segmentation of the nuclei was detected in
the Tet2-deficient animals (Figures 6B and 6D; data not shown).
Moreover, Tet2/ mice had significantly enlarged spleens
(Figure 6C) compared to littermate controls (p < 0.05). Detailed
pathologic analysis revealed that approximately all Tet2/
mice by week 20 developed significant splenomegaly (spleen
weight >250 mg), consistent with significant myeloproliferation.
Histopathologic analysis revealed that Tet2/ mice, but not
Tet2+/+ littermate controls, had prominent histologic evidence
of disease, including significant destruction of spleen architec-
ture, infiltration of the liver and lung, as well as bonemarrow neu-
trophilia and monocytosis (Figure 6D). FACS analysis of the
spleen of these mice revealed a significant enlargement of
both the CD11b+ and CD11b+Gr1+ populations, consistent
with granulocytic and monocytic expansion (Figure 6E). Collec-
tively, these studies demonstrate that Tet2 loss is associated
with myeloproliferation in vivo, and suggest that TET2mutations
contribute to increased stem cell self-renewal and to progressive
myeloid expansion in vivo. Although splenomegaly and leukocy-
tosis are observed in a spectrum of myeloid malignancies, the
constellation of splenomegaly, extramedullary hematopoiesis,
neutrophilia, and monocytosis is most consistent with human
CMML. TET2mutations are most commonly observed in human
CMML, with somatic loss-of-function mutations in more than
40% of well-annotated CMML patient cohorts (Abdel-Wahab
et al., 2009; Jankowska et al., 2009). In agreement with the
murine data, detailed clinical and molecular analysis of patients
with CMML revealed that patients with TET2-mutant CMML pre-
sented with splenomegaly, elevated peripheral blood WBC, and
monocytosis (Figure S1B). Moreover, TET2-mutant CMML was
characterized by a paucity of co-occurring cytogenetic abnor-
malities: 5.9% of patients with TET2 mutant had cytogenetic
abnormalities versus 61.3% of patients with TET2-wild-type
CMML (p = 0.018) (Figures S1B and S1C). These studies sug-
gested that Tet2 deletion leads to progressive myeloproliferation
in vivo with cardinal features of human CMML.
Tet2 Haploinsufficiency Is Sufficient to Initiate Aberrant
Hematopoiesis In Vitro and In Vivo
Although a small subset of patients with leukemia presents with
biallelic TET2mutations and/or deletions, themajority of patients
present with monoallelic TET2 loss (Abdel-Wahab et al., 2009;Jankowska et al., 2009). We performed DNA and cDNA
sequencing of patient samples with monoallelic TET2mutations
and demonstrated that these patients continue to express the
wild-type allele (Figure S6). These data suggest the possibility
that haploinsufficiency for TET2 may result in alterations in self-
renewal, hematopoietic differentiation, and susceptibility to
myeloid transformation. Therefore, we performed phenotypic
analysis of Tet2+/ (Vav-Cre+Tet2WT/f) mice. We first purified
CD150+ HSC from the bone marrow of Tet2 heterozygotes and
plated them in methylcellulose cultures. Similar to Tet2/ cells,
Tet2+/ cells were able to serially replate (Figure 7A), unlike
wild-type HSC that failed to generate colonies after the second
plating. Likewise, Tet2+/ cells generated colonies with a similar
immunophenotype as Tet2/ cells. This was demonstrated by
an immature, promyeloblastic morphology and the upregulation
of the cell surface markers c-Kit, CD34, and FcgR (Figures 7B
and 7C; data not shown). Furthermore, competitive reconstitu-
tion experiments, performed as described in Figure 5A, demon-
strated that Tet2+/, but not Tet2+/+, cells were able to outcom-
pete wild-type counterparts, albeit with slower kinetics than
Tet2/ cells (Figures 7D–7H). Indeed, 23 weeks post-deletion,
more than 70%of peripheral blood cells were Tet2+/, consistent
with increased long-term self-renewal with loss of a single Tet2
allele. Moreover, in a noncompetitive setting, 20-week-old
Vav-Cre+Tet2WT/fmice showed increased circulating monocytes
(Figure 7I) andextramedullary hematopoiesis (Figures 7Jand7K),
with a significant increase of both Lineageneg c-Kit+ and LSK cells
(Figure 7J; data not shown). These data clearly demonstrate that
Tet2 loss leads to dose-dependent effects on hematopoiesis and
on myeloid transformation, and that monoallelic TET2 loss is an
important pathogenetic event in myeloid malignancies.
DISCUSSION
The identification of recurrent somatic loss-of-function muta-
tions in TET2 provides genetic evidence that mutational inactiva-
tion of enzymes that regulate cytosine hydroxymethylation is
a common pathogenetic event in myeloid malignancies
(Delhommeau et al., 2009; Ko et al., 2010; Langemeijer et al.,
2009). In addition, genetic and functional studies suggest that
neomorphic IDHmutations contribute tomyeloid transformation,
at least in part, by inhibiting TET enzymatic function (Figueroa
et al., 2010; Xu et al., 2011). Although genetic and in vitro studies
suggested a role for TET2 in regulating hematopoietic differenti-
ation and stem/progenitor cell expansion, to our knowledge, the
in vivo effects of Tet2 loss had not previously been described.
Here, we report the effects of Tet2 loss in the hematopoietic
compartment, which has allowed us to make several important
observations. First, we found that Tet2 loss leads to increased
replating capacity in vitro, and that Tet2-deficient cells had
enhanced repopulating activity in competitive reconstitution
assays consistent with enhanced HSC function in vivo. Second,
Tet2 loss led to progressive myeloproliferation in vivo, with
features characteristic of human CMML. In addition we found
that Tet2 haploinsufficiency confers increased self-renewal to
stem/progenitor cells and to extramedullary hematopoiesis,
suggesting that heterozygous loss of TET2, as is commonly
observed in myeloid malignancies, is sufficient to contribute to
myeloid transformation in vivo.Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc. 17
Figure 5. Tet2–/– Hematopoietic Stem Cells Show Increased Repopulating Ability Consistent with Increased Self-Renewal
(A) Schematic depiction of the competitive transplantation scheme. Tet2/ cells are double positive for CD45.1/CD45.2markers. Tet2wild-type cells are CD45.2
single positive cells.
(B) Percentage of CD45.1 versus CD45.2 total chimerism in the peripheral blood of recipient animals (n = 15 for each genotype). Time (weeks) denotes the time
after the termination of polyI-polyC injections.
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Tet2 Controls HSC Development and TransformationOur in vivo investigation of the effects of Tet2 loss is consis-
tent with several observations emanating from previous genetic
and functional studies. The presence of TET2 mutations in
a significant proportion of patients with MPN, MDS, and AML
is consistent with the notion that TET2 loss confers increased
self-renewal to stem/progenitor cells in vivo, which then leads
to acquisition of mutations that direct the phenotype of TET2-
mutant hematopoietic cells (Haeno et al., 2009; Tefferi, 2010).
These data are also consistent with previous xenotransplanta-
tion studies of a small cohort of TET2 mutant primary MPN
samples that demonstrated that TET2-mutant MPN cells could
engraft NOD-SCID mice (Delhommeau et al., 2009). In addition,
genetic studies of patients with MPN that subsequently trans-
formed to AML identified TET2 mutations as a recurrent
somatic mutation during progression from MPN to AML
(Abdel-Wahab et al., 2010; Schaub et al., 2010). Our data impli-
cate increased self-renewal as a putative mechanism of trans-
formation by TET2 mutations, which contribute to disease
initiation and progression. Our transcriptional data suggest
that Tet2 loss leads to increased expression of myeloid-specific
and self-renewal gene programs. However, subsequent studies
will have to functionally investigate which downstream targets
of Tet2 loss are required to confer enhanced self-renewal on
stem/progenitor cells. Recent work suggested that TET
proteins regulate embryonic stem cell self-renewal and differen-
tiation (Ito et al., 2010; Koh et al., 2011). Taken together, the
data suggest that Tet2 deletion likely has effects at multiple
stages in hematopoietic differentiation, and that regulation of
hydroxymethylation by TET enzymes controls stem cell self-
renewal and differentiation in different cellular contexts.
However, to our knowledge, the exact mechanisms by which
perturbations in TET enzyme function remain to be delineated.
This is particularly evident given recent studies suggesting
a dynamic interplay between changes in TET1-mediared hy-
droxymethylation and other epigenetic marks in regulating
gene expression (Ficz et al., 2011; Williams et al., 2011; Wu
et al., 2011), and it is likely additional alterations in the epige-
netic state cooperate with TET2 mutations in malignant
transformation.
In addition to effects of Tet2 loss on self-renewal, we found
that Tet2 loss led to progressive myeloproliferation in vivo. Two
recent studies used RNAi-mediated Tet2 knockdown in vitro to
suggest that TET2 depletion led to impaired hematopoietic
differentiation and to preferential myeloid commitment (Figueroa
et al., 2010; Ko et al., 2010). These data are consistent with our
in vivo data because we observe progressive hematopoietic
stem/progenitor cell expansion and myeloproliferation in vivo
with Tet2 deletion or haploinsufficiency notable for neutrophilia,
monocytosis, and splenomegaly. Although these features are
seen, to a varying degree, in different myeloid malignancies,
they are most commonly observed in human CMML, suggesting(C) Representative FACS plots showing CD45.1/CD45.2 (Tet2/) and CD45.2 (Te
CD11b+, and lymphoid B220+ cells. Two time points (weeks 0 and 23) are shown
(D) Representative FACS plots showing CD45.1/CD45.2 (Tet2/) and CD45.2 (
progenitor (MPP1, MPP2, and CMP) compartments. Analysis performed at week
(E) Similar stainings quantifying CD45.1/CD45.2 (Tet2/) and CD45.2 (Tet2+/+)
populations. Week 23 stainings are shown (n = 5 for each genotype). Error bars
See also Figure S4.that Tet2 loss in the absence of other genetic lesions favors
progressive myelomonocytic expansion. This is consistent with
the observations that TET2 mutations are most common in
CMML (Abdel-Wahab et al., 2009; Jankowska et al., 2009) and
that TET2-mutant CMML is characterized by fewer additional
somatic cytogenetic alterations compared to TET2-wild-type
CMML (Figures S1B and S1C). Most importantly, we demon-
strate that Tet2 haploinsufficiency is sufficient to confer
increased self-renewal to stem/progenitor cells and to promote
myeloproliferation in vivo. Given that the vast majority of patients
with TET2-mutant hematopoietic malignancies retain a wild-type
copy of TET2, our data provide functional evidence that loss of
a single TET2 allele can contribute to transformation.
Collectively, the presented data implicate TET2 as a master
regulator of normal and malignant hematopoiesis. It is likely
that TET2 has distinct roles in other hematopoietic lineages,
and may contribute to transformation in lymphoid malignancies
or even in epithelial tumors. These data also suggest that
dysregulation of hydroxymethylation by mutations in the TET
family of enzymes and by other somatic mutations may
contribute to malignant transformation in other contexts. In
addition it is possible that therapies that modulate hydroxyme-
thylation levels might be of benefit in malignancies character-
ized by loss of TET enzyme function by inhibiting malignant
stem cell self-renewal. Moreover, our studies provide insight
into mechanisms of transformation by a novel class of muta-
tions found in myeloid malignancies and in other tumors, and
we predict that subsequent studies will identify additional muta-




All animals were housed at New York University School of Medicine or at
Memorial Sloan-Kettering Cancer Center. All animal procedures were con-
ducted in accordance with the Guidelines for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Commit-
tees (IACUCs) at New York University School of Medicine andMemorial Sloan-
Kettering Cancer Center.
Generation of Tet2-Deficient Mice
The Tet2 allele was deleted by targeting exon 3. Briefly, we have inserted two
LoxP sites flanking exon 3, as well as an Frt-flanked neomycin selection
cassette in the upstream intron (Figure 3A). Ten micrograms of the targeting
vector was linearized by NotI and then transfected by electroporation of
BAC-BA1 (C57BL/63 129/SvEv) hybrid embryonic stem cells. After selection
with G418 antibiotic, surviving clones were expanded for PCR analysis to
identify recombinant ES clones. Secondary confirmation of positive clones
identified by PCR was performed by Southern blotting analysis. DNA was
digested with ScaI and electrophoretically separated on a 0.8% agarose gel.
After transfer to a nylon membrane, the digested DNA was hybridized with
a probe targeted against the 30 or 50 external region. DNA from C57Bl/6 (B6),
129/SvEv (129), and BA1 (C57Bl/6 3 129/SvEv) (Hybrid) mouse strains wast2+/+) stainings and chimerism in whole peripheral mononuclear cells, myeloid
.
Tet2+/+) stainings and chimerism within the bone marrow stem (LT-HSC) and
23 after polyI-polyC injection.
expression in bone marrow myeloid (CD11b+) and lymphoid (B220+) mature
represent ± SD.
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Figure 6. Tet2–/– Animals Develop Myeloid Neoplasia Reminiscent of Human CMML
(A) Left panel shows automated peripheral blood enumeration of whole blood cells (WBC). Right panel illustrates manual differential counts of neutrophils and
monocytes showing blood monocytosis (nR 3 for each genotype).
(B) Representative images of peripheral blood smears from Tet2+/+ and Tet2/ mice at 20 weeks of age (nR 3 for each genotype).
(C) Splenomegaly in 20-week-old Tet2/ (Vav-Cre+Tet2f/f) animals. Littermate wild-type (Vav-Cre+Tet2WT/WT) controls at 20 weeks are used (n = 5 mice).
(D) Histologic (H&E) analysis of Tet2/ and control tissues (bone marrow, spleen, liver, and lung) is shown, illustrating disrupted spleen architecture, monocytic
infiltrations in liver and lung, and bone marrow neutrophilia (n = 5 for each genotype).
(E) Left panels show FACS analysis of spleen CD11b and Gr-1-expressing populations. A representative FACS plot from each genotype is shown. Right panel
illustrates total cell number of CD11b+ cells in the spleen of Tet2+/+ and Tet2/ mice at 20 weeks of age. Error bars represent ± SD.
See also Figure S5.
Cancer Cell
Tet2 Controls HSC Development and Transformationused as wild-type controls. Positive ES clones were expanded and injected
into blastocysts.
The generated mice (Tet2f/f) were initially crossed to a germline Flp-deleter
(Jackson Laboratories), to eliminate the neomycin cassette, and subsequently
to the IFNa-inducible Mx1-cre (Jackson Laboratories), the hematopoietic-
specific Vav-cre, and the germline EIIa-cre (Ku¨hn et al., 1995; Stadtfeld and
Graf, 2005; Lakso et al., 1996). The Vav-Cre transgenic line was generated
by the Graf laboratory (Stadtfeld and Graf, 2005) and was a gift from Virginia
Shapiro (Mayo Clinic).20 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.In Vivo Studies
Tet2 conditional and control mice received five intraperitoneal injections of
poly(I:C) every other day at a dose of 20 mg/g of bodyweight starting at 2weeks
post-birth. For the hematopoietic-specific Vav-cre line, Tet2f/f VavCre+, Tet2f/w
VavCre+, and Tet2w/w VavCre+mice were analyzed between 2 and 20 weeks of
age. Thymus, bone marrow, spleen, and peripheral blood were analyzed by
flow cytometry and formalin-fixed paraffin-embedded tissue sections stained
with hematoxylin and eosin. Peripheral blood was smeared on a slide and
stained using the Giemsa-Wright staining method. Tissue sections and blood
Table 1. Tet2 Deficiency Leads to Progressive Peripheral
Leukocytosis
Genotype WBC (3 109/l) HCT (%) PLT (3 109/l) No.
4–6 Weeks
Tet2+/+ 5.48 ± 1.54 40.32 ± 8.70 367 ± 66 11
Tet2+/ 6.61 ± 1.95 49.63 ± 5.90 365 ± 59 7
Tet2/ 6.66 ± 2.04 50.06 ± 4.70 352 ± 85 9
20 Weeks
Tet2+/+ 5.43 ± 1.35 46.29 ± 5.56 498 ± 171 8
Tet2+/– 8.77 ± 1.90a 52.55 ± 4.42 559 ± 119 10
Tet2/ 10.00 ± 2.28a 52.45 ± 11.18 517 ± 124 13




Tet2 Controls HSC Development and Transformationsmears were evaluated by a hematopathologist. Deletion of the Tet2 allele and
transcript was measured by genomic PCR and quantitative real-time PCR.Gene Expression Analysis
LSK and CMP cells were sorted from Tet2+/+ Mx-1+, Tet/Mx-1+ littermate
mice 4 weeks post-deletion via pIC injection. Additionally, cells were obtained
from serial replating of CD150+-sorted Tet2-deficient cells. RNA was isolated
using RNeasy RNA isolation kit (QIAGEN) according to manufacturer’s
protocol. A portion of total RNA (5 ng) from target cell populations was ampli-
fied and then labeled with the Ovation RNA Amplification System v2 and
Ovation cDNA Biotin System (NuGEN). The resulting cDNA was hybridized
to GeneChip MG 430 2.0 arrays according to the array manufacturer’s recom-
mendations (Affymetrix). The Affymetrix gene expression-profiling data were
normalized using the previously published Robust Multi-array Average
(RMA) algorithm using the GeneSpring GX software (Agilent, Palo Alto, CA,
USA). The gene expression intensity presentation was generated with Gene-
Spring GX software and Multi Experiment Viewer software. Hierarchical clus-
tering on genes and samples was performed using Euclidean distance as
a metric and average linkage method (Bolstad et al., 2003).Gene Set Enrichment Analysis
Gene Set Enrichment Analysis was performed using GSEA (Subramanian
et al., 2005) http://www.broadinstitute.org/gsea/, using gene set as permuta-
tion type, 1000 permutations, and log2 ratio of classes as metric for ranking
genes. Independent stem cell gene expression signatures are obtained by
http://franklin.imgen.bcm.tmc.edu and Ng et al. (2009).
The ‘‘CMP signature’’ gene sets were generated using a systematic
approach based on the comparison of gene expression arrays from wild-
type LSK and wild-type GMP. Genes that were significantly modulated in
CMP compared to LSK (over 1.33-fold; p < 0.05) were used to define CMP
versus LSK_UP gene set containing upregulated genes and CMP versus
LSK_DWN containing downregulated genes.In Vitro Colony-Forming Assays
CD150+ LSK aswell as ckit+ cells were sorted from the bonemarrow of Tet2/
VavCre+, Tet2+/ MxCre+, Tet2/ Mx-1Cre+, Tet2+/+ VavCre+, or Tet2+/+
Mx-1Cre+ mice and seeded at a density of 500 cells/replicate for the
CD150+ subset and 2000 cells/replicate for the cKit+ subset into cytokine-sup-
plemented methylcellulose medium (Methocult, M3434; STEMCELL Technol-
ogies). Colonies propagated in culture were scored at day 7. Representative
colonies were isolated from the plate for cytospins. Remaining cells were
resuspended, counted, and a portion was stained for c-kit (clone 2B8;
BioLegend), and replated (4000 cells/replicate) for a total of 5 platings (7, 14,
21, 28, and 35 days). Cytospins were performed by resuspending in warm
PBS and spun onto the slides at 350 3 g for 5 min. Slides were air-dried
and stained using the Giemsa-Wright method.Bone Marrow Transplantation
Freshly dissected femurs and tibias were isolated from Tet2w/w Mx-1Cre+
CD45.2+, Tet2f/w Mx-1Cre+CD45.2+, or Tet2f/f Mx-1Cre+ CD45.1+/CD45.2+
mice. Hence, Tet2-deficient animals are expressing both CD45.2 and
CD45.1 markers, whereas Tet2 heterozygous animals and Tet2 wild-type
control animals are expressing only the CD45.2 marker. Bone marrow was
flushed with a 1 cc insulin syringe into PBS supplemented with 3% fetal bovine
serum. The bone marrow was spun at 0.53 g by centrifugation at 4C, and red
blood cells were lysed in ammonium chloride-potassium bicarbonate lysis
buffer for 3 min on ice. After centrifugation, cells were resuspended in PBS
plus 3% FBS, passed through a cell strainer, and counted. Finally, 0.5 3 106
total bone marrow cells of Tet2w/w Mx-1Cre+ CD45.2+, Tet2f/w
Mx-1Cre+CD45.2+, or Tet2f/f Mx-1Cre+ CD45.1+/CD45.2+ cells were mixed
with 0.5 3 106 wild-type CD45.1+-support bone marrow and transplanted
via retro-orbital injection into lethally irradiated (two times 550 Gy) CD45.1+
host mice. Chimerism was measured by FACS in peripheral blood at 4 weeks
post-transplant (week 0, pre-polyI-polyC). Deletion of Tet2was initiated at this
time point via five intraperitoneal injections of polyI-polyC at a dose of 20 mg/g
of body weight. Chimerism for the duration of the experiment was subse-
quently followed via FACS in the peripheral blood every 2 weeks (week 0, 2,
4, 6, 8, 10, 12, 14, and 16 after polyI-polyC injection). Additionally, for each
bleeding, whole blood cell counts were measured on a blood analyzer, and
peripheral blood smears were scored. Chimerism in the bone marrow, spleen,
and thymus was evaluated at 10 and 14 weeks via animal sacrifice and subse-
quent FACS analysis.
Mouse Bone Marrow Infections and shRNA Colony Assays
Bone marrow was harvested from the femur of wild-type C57Bl/6 mice. After
red cell lysis, the bone marrow was cultured in media containing RPMI/10%
FBS and IL-3 (7 ng/ml), IL-6 (10 ng/ml), and stem cell factor (10 ng/ml). The
next day, cells were infected with MSCV retroviral vectors for control and
Tet2 shRNAs containing IRES GFP. Targets for shRNAs can be found in
Supplemental Experimental Procedures. Cells were infected twice in the
presence of polybrene and then sorted for GFP+ cells 48 hr following second
infection. A total of 13 104 cells was plated per well in Methocult (STEMCELL
Technologies) supplemented with IL-3 (20 ng/ml), IL-6 (10 ng/ml), SCF
(10 ng/ml), GMCSF (10 ng/ml), TPO (50 ng/ml), and Flt3L (100 ng/ml). Colonies
were scored 14 days after seeding, recollected in PBS, and then recultured in
Methocult at 13 104 cells. Tet2 knockdown was confirmed by qRT-PCR using
Thermo Scientific Verso cDNA Kit and SYBR green quantification in an ABI
7500 sequence detection system.
5hmC Quantification
Genomic DNA was purified using Purgene DNA purification kit (QIAGEN).
Genomic DNA was hydrolyzed and analyzed in triplicate for the relative levels
of 5hmC by liquid chromatography-electrospray ionization tandem mass
spectrometry (Shah et al., 2010).
Patient Samples and Sequencing
Approval was obtained from the institutional review boards of Memorial Sloan-
Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson
Cancer Center. Patients provided written informed consent in all cases at
time of enrollment. DNA sequencing methods and primer sequences for
TET2 have been described previously (Abdel-Wahab et al., 2009). A total of
389 AML samples were obtained at diagnosis from patients enrolled in the
Eastern Cooperative Oncology Group’s (ECOG) E1900 clinical trial. Samples
were deidentified at the time of inclusion. A total of 354 MPN, 69 CMML,
and an additional 119 AML samples were analyzed with characteristics
previously described (Abdel-Wahab et al., 2009). Approval was obtained
from the institutional review boards of Memorial Sloan-Kettering Cancer
Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center.
DNA sequencing methods and primer sequences for TET2 have been
described previously (Abdel-Wahab et al., 2009).
Human CD34+ Stem Cell Isolation
Peripheral blood was collected from normal bone marrow transplant donors
who underwent stem cell mobilization with GCSF. Remainder excess aliquots
were used for CD34+ cell isolation. CD34+ HSPCs were purified by positiveCancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc. 21
Figure 7. Tet2 Haploinsufficiency Is Able to Initiate Aberrant In Vitro and In Vivo Hematopoiesis
(A) Methylcellulose CFU assay using LSK CD150+ cells (Lin, cKit+, Sca-1+, CD150+). An average of the absolute number of colonies is shown for sequential
platings (1–5) (n = 5).
(B) Representative FACS plot of colony-forming assay showing c-Kit expression at the 2nd and 4th plating.
(C) Giemsa-Wright staining of colonies formed from Tet2+/ CD150+ LSKs (Vav-Cre+Tet2WT/f). Images of cytospins are shown.
(D) Graph represents chimerism between CD45.2 (Tet2+/) and CD45.1 (Tet2+/+) in the peripheral blood from a competitive transplantation assay over time
(0–23 weeks). Experimental strategy is described in Figure 5A. Blue line indicates wild-type:wild-type cohorts, and red indicates Tet2+/:wild-type cohorts (n = 5
mice).
(E) Representative FACS plots showing CD45.1/CD45.2 chimerism in the peripheral blood from CD45.1 (Tet2+/+) and CD45.2 (Tet2+/) cohorts before (week 0)
and after deletion (23 weeks after polyI-polyC).
(F–H) Representative FACS plots showing CD45.1 (Tet2+/+)/CD45.2 (Tet2+/) chimerism at 23 weeks post-deletion in myeloid and lymphoid populations in the
peripheral blood (F), in the bone marrow (G), and in the bone marrow stem and progenitor cell compartment (H).
(I) Left panel shows automated peripheral blood enumeration of whole blood cells (WBC). Right panel illustrates manual differential counts of neutrophils and
monocytes showing monocytosis (nR 3 for each genotype).
(J) Representative FACS plot showing increased frequency of LSKs in the spleen of Tet2+/ mice. Right panel depicts absolute number of LSKs in the spleen of
wild-type and Tet2+/ mice (n = 5 for each genotype).
(K) H&E of spleen from 20-week-old Tet2+/ mice. Error bars represent ± SD.
See also Figure S6.
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Tet2 Controls HSC Development and Transformationselection using the Midi-magnetic-activated cell sorting LS+ separation
columns and isolation kit (Miltenyi). RNA was collected using the QIAGEN
RNeasy kit.ACCESSION NUMBERS
Microarray data can be accessed under GEO accession number GSE27816.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:10.
1016/j.ccr.2011.06.001.
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